JP2018514565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514565A5 JP2018514565A5 JP2017556902A JP2017556902A JP2018514565A5 JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5 JP 2017556902 A JP2017556902 A JP 2017556902A JP 2017556902 A JP2017556902 A JP 2017556902A JP 2018514565 A5 JP2018514565 A5 JP 2018514565A5
- Authority
- JP
- Japan
- Prior art keywords
- depot
- vaccine
- seq
- forming
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 82
- 239000000427 antigen Substances 0.000 claims 45
- 102000036639 antigens Human genes 0.000 claims 45
- 108091007433 antigens Proteins 0.000 claims 44
- 230000015572 biosynthetic process Effects 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 230000028993 immune response Effects 0.000 claims 8
- 241000701806 Human papillomavirus Species 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- 108010002687 Survivin Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 239000012051 hydrophobic carrier Substances 0.000 claims 4
- 230000002209 hydrophobic effect Effects 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000004543 DNA replication Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000003921 oil Substances 0.000 claims 3
- 102000000763 Survivin Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- -1 cholesterol lipid Chemical class 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 2
- 239000002480 mineral oil Substances 0.000 claims 2
- 235000010446 mineral oil Nutrition 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000588832 Bordetella pertussis Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 206010022095 Injection Site reaction Diseases 0.000 claims 1
- 241000223810 Plasmodium vivax Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155677P | 2015-05-01 | 2015-05-01 | |
| US62/155,677 | 2015-05-01 | ||
| PCT/CA2016/050487 WO2016176761A1 (en) | 2015-05-01 | 2016-04-27 | Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514565A JP2018514565A (ja) | 2018-06-07 |
| JP2018514565A5 true JP2018514565A5 (cg-RX-API-DMAC7.html) | 2019-05-23 |
| JP6851983B2 JP6851983B2 (ja) | 2021-03-31 |
Family
ID=57217405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556902A Expired - Fee Related JP6851983B2 (ja) | 2015-05-01 | 2016-04-27 | デポー形成及びデポー非形成ワクチンを使用して免疫応答を強化する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180162913A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3288538A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6851983B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016176761A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018509384A (ja) | 2015-01-06 | 2018-04-05 | イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． | リピドａ模倣体、調製方法、及びその使用 |
| CA3022924A1 (en) | 2016-05-04 | 2017-11-09 | Immunovaccine Technologies Inc. | Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof |
| NZ749355A (en) | 2016-05-27 | 2023-04-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
| CA3038155A1 (en) | 2016-09-27 | 2018-04-05 | Immunovaccine Technologies Inc. | Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects |
| EP3582790A4 (en) * | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| CN109456405B (zh) * | 2017-09-06 | 2022-02-08 | 上海交通大学医学院附属仁济医院 | 一种去棕榈酰化pd-l1蛋白质及其制备方法和应用 |
| EP3706713A4 (en) * | 2017-11-09 | 2021-06-16 | ImmunoVaccine Technologies Inc. | PHARMACEUTICAL COMPOSITIONS, METHOD OF MANUFACTURING THEREOF, INCLUDING SIZING OF LIPID VESICLE PARTICLES, AND USES |
| CN107988373A (zh) * | 2018-01-10 | 2018-05-04 | 上海交通大学医学院附属仁济医院 | 用于预测癌症免疫治疗效果的生物标志物、试剂盒与应用 |
| EP3768242A4 (en) * | 2018-03-20 | 2021-12-08 | ImmunoVaccine Technologies Inc. | METHODS AND COMPOSITIONS FOR THE TARGETED DELIVERY OF ACTIVE SUBSTANCES AND IMMUNMODULATORY AGENTS TO LYMPH NODES |
| CA3110760A1 (en) | 2018-09-04 | 2020-03-12 | Treos Bio Limited | Peptide vaccines |
| US20220125903A1 (en) * | 2018-11-19 | 2022-04-28 | Immunovaccine Technologies Inc. | Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors |
| WO2024186623A1 (en) | 2023-03-03 | 2024-09-12 | BioVaxys Inc. | Methods of making dried pharmaceutical compositions |
| WO2024186646A1 (en) | 2023-03-03 | 2024-09-12 | BioVaxys Inc. | Methods of making lipid adjuvanted compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US7601801B2 (en) * | 2003-07-11 | 2009-10-13 | Dainippon Sumitomo Pharma Co., Ltd. | HLA-A24 binding cancer antigen peptide derived from livin |
| US7749520B2 (en) * | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| JP2008532929A (ja) * | 2005-02-01 | 2008-08-21 | メディバス エルエルシー | ワクチン送達組成物および使用法 |
| CA2523032A1 (en) * | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| US7947286B2 (en) * | 2005-10-07 | 2011-05-24 | Panthera Biopharma Llc | Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain |
| WO2009025770A2 (en) * | 2007-08-17 | 2009-02-26 | Wyeth | A heterologous prime-boost immunization regimen |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| WO2009146523A1 (en) * | 2008-06-05 | 2009-12-10 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| US20130115234A1 (en) * | 2010-03-26 | 2013-05-09 | Emergent Product Development Gaithersburg,Inc. | Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof |
| US9889192B2 (en) * | 2012-10-01 | 2018-02-13 | Thomas Jefferson University | Immunization with rabies virus vector expressing foreign protein antigen |
| WO2014153636A1 (en) * | 2013-03-27 | 2014-10-02 | Immunovaccine Technologies Inc. | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |
-
2016
- 2016-04-27 JP JP2017556902A patent/JP6851983B2/ja not_active Expired - Fee Related
- 2016-04-27 WO PCT/CA2016/050487 patent/WO2016176761A1/en not_active Ceased
- 2016-04-27 US US15/571,003 patent/US20180162913A1/en not_active Abandoned
- 2016-04-27 EP EP16788982.3A patent/EP3288538A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514565A5 (cg-RX-API-DMAC7.html) | ||
| Yang et al. | Recent advances in the development of toll-like receptor agonist-based vaccine adjuvants for infectious diseases | |
| Moni et al. | Advancements in vaccine adjuvants: the journey from alum to nano formulations | |
| Facciolà et al. | An overview of vaccine adjuvants: current evidence and future perspectives | |
| Wang et al. | Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity | |
| Tornesello et al. | Nanoparticles to improve the efficacy of peptide-based cancer vaccines | |
| Cunningham et al. | Vaccine development: From concept to early clinical testing | |
| TWI672149B (zh) | 改良之疫苗組成物及使用方法 | |
| Gomes et al. | Harnessing nanoparticles for immunomodulation and vaccines | |
| Martiñón et al. | Chemical and immunological characteristics of aluminum‐based, oil‐water emulsion, and bacterial‐origin adjuvants | |
| Alving et al. | Adjuvants for human vaccines | |
| JP2014520807A5 (cg-RX-API-DMAC7.html) | ||
| JP2018534304A5 (cg-RX-API-DMAC7.html) | ||
| Levast et al. | Vaccine potentiation by combination adjuvants | |
| Goetz et al. | Vaccine adjuvants for infectious disease in the clinic | |
| Even-Or et al. | Adjuvanted influenza vaccines | |
| JP2014522842A5 (cg-RX-API-DMAC7.html) | ||
| RU2009144125A (ru) | Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе | |
| JP2013181034A5 (cg-RX-API-DMAC7.html) | ||
| JP2014532620A5 (cg-RX-API-DMAC7.html) | ||
| Ireton et al. | Adjuvants containing natural and synthetic Toll-like receptor 4 ligands | |
| JP2007505033A5 (cg-RX-API-DMAC7.html) | ||
| JP7409594B2 (ja) | 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 | |
| CN103768595A (zh) | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 | |
| Dong et al. | Monophosphoryl Lipid A‐Adjuvanted Virosomes with Ni‐Chelating Lipids for Attachment of Conserved Viral Proteins as Cross‐Protective Influenza Vaccine |